Tag: BT001
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 – 11/14/2022 at 08:00
Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in…
Transgene and BioInvent win the Best Article award in the Oncolytic and Local Immunotherapy category awarded by the JITC, for their work on BT-001 – 2022-11-14 at 08:00
Article, Featured at SITC 2022, Demonstrates the Potential of Innovative Anti-CTLA-4 Antibody Delivery This award further highlights the potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent, currently…